Opioid Agonist Treatment: novel formulations and challenges

Auditorium IV
In programme
Thursday, 24 October, 2024 - 10:50 to 12:20
View presentations

About

This session will explore innovative approaches and current challenges in OAT. Key themes include the importance of community-led monitoring to ensure the quality, satisfaction, and accessibility of OAT programs, adaptation in response to supply chain disruptions caused by COVID-19, understanding patient experiences and outcomes, and qualitative insights on long-acting injectable buprenorphine effectiveness and acceptability.

Chair

Fonseca Francina
  • Head of Addiction Unit,
  • Institut de Salut Mental, Hospital del Mar,
  • Spain
Socias M. Eugenia
  • Assistant Professor,
  • University of British Columbia

Type

Tracks

Keywords

Presentations

Thursday, 24 October

10:50
Oral presentation

Long-acting injectable buprenorphine for opioid use disorder: key findings from a longitudinal qualitative study

10:50 to 12:20
Auditorium IV
Joanne Neale
Oral presentation

Associations between opioid agonist therapy exposure and chronic pain characteristics among people who inject drugs

10:50 to 12:20
Auditorium IV
Sasha Udhesister
Oral presentation

Adapting Opioid Therapy: Transition from Methadone to Slow-Release Morphine Amid COVID-19 Supply Chain Disruptions

10:50 to 12:20
Auditorium IV
Artūras Barkus
Oral presentation

Impact of long-acting depot buprenorphine post-release from custody– Early findings from the Release Study

10:50 to 12:20
Auditorium IV
Adrian Dunlop
View the programme